Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes

Journal of Hepatology

Volumn 28, Issue 1, 1998, Pages 99-106

  Benz, Christine ^a   Angermüller, Sabine ^a   Töx, Ulrich ^a   Klöters Plachky, Petra ^a   Riedel, Hans Dieter ^a   Sauer, Peter ^a   Stremmel, Wolfgang ^a   Stiehl, Adolf ^a  

^a NONE

Author keywords

Apoptosis; Bile acid; Cytolysis; Rat hepatocytes; Tauroursodeoxycholic acid

Indexed keywords

BILE ACID; DNA FRAGMENT; GLYCOCHENODEOXYCHOLIC ACID; LIVER ENZYME; TAUROURSODEOXYCHOLIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CHOLESTASIS; CYTOLYSIS; ENZYME RELEASE; LIVER CELL; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031911131     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80208-0     Document Type: Article

References (24)

1. Greim H, Trülzsch D, Czygan P, Rudick J, Hutterer F, Schaffner F, et al. Mechanisms of cholestasis 6. Bile acids in human livers with and without biliary obstruction. Gastroenterology. 63:1972;837-845.
2. Leuschner U, Fischer H, Kurtz W, Güldütuna Hubner K, Hellstern A, Gatzen M, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double blind trial. Gastroenterology. 97:1989;1268-1274.
3. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 324:1991;1548-1554.
4. Lindor KDL, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 106:1994;1284-1290.
5. Heathcote EJL, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multi-center double-blind controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
6. Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheler DE, et al. A randomized, double-blind placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 22:1995;759-766.
7. Beuers U, Spengler U, Kruis W, Aydemir Ü, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 16:1992;707-714.
8. Stiehl A, Walker S, Sziehl L, Rudolph G, Hofmann WJ, Theilmann L. Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. 20:1994;57-64.
9. Patel T, Spivey J, Vadakalan J, Gores GJ. Apoptosis - an alternative mechanism of bile salt toxicity. Paumgartner G, Beuers U. Bile Acids in Liver Diseases. 1995;96-100 MTP Press, London.
10. Patel T, Gores G. Apoptosis and hepatobiliary disease. Hepatology. 21:1995;1725-1741.
11. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest. 94:1994;2183-2192.
12. Billington D, Evans CE, Godfrey PP, Coleman R. Effects of bile acids on the plasma membranes of isolated rat hepatocytes. Biochem J. 88:1980;321-327.
13. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 30:1989;719-730.
14. Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology. 106:1994;1333-1341.
15. Seglen PO. Preparation of isolated rat liver cells. Prescott DM. Methods in Cell Biology. 13:1976;29-83 Academic Press, New York.
16. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology. 12:1990;486-491.
17. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic Z. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrpohobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology. 14:1991;920-926.
18. Ohiwa T, Katagiri K, Hoshino M, Hayakawa T, Nakai T. Tauroursodeoxycholate and tauro-β-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. Hepatology. 17:1993;470-476.
19. Hillaire S, Ballet F, Franco D, Setchell KDR, Poupon R. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology. 20:1994;1595-1601.
20. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology. 20:1994;1595-1601.
21. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochendeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther. 272:1995;930-938.
22. Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick GA, et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology. 110:1996;1553-1563.
23. Kwo P, Patel T, Bronk S, Gores GJ. Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. Am J Physiol. 268:1995;G613-G621.
24. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif. 24:1991;203-214.